Daniel Heng
@DrDanielHeng
Followers
4K
Following
9K
Media
167
Statuses
2K
A medical oncologist that specializes in and focuses his research on urologic cancers.
Calgary, Alberta
Joined June 2016
We have moved to the Arthur Child Comprehensive Cancer Centre in Calgary! The largest free-standing cancer centre in Canada! $1.4 billion investment in patient care, research and hope. I love our team!@AHS_CancerCare @AHS_media @UCalgaryMed #YYC #medonc
8
12
89
Congrats @crisbergerot who keeps pushing the boundaries in #kidneycancer QOL metrics! now, a new paper in EU Oncology!
5
15
52
Indeed, @tompowles1 continues to tailor, guide and define the Standard of Care in Bladder Cancers one year after another.
This is huge. Congrats to @tompowles1 @BartsECMC & team who took this from a brilliant paper in @Nature in 2021 to a paradigm-shifting + P3 trial. @BladderCancerUS @IBCG_BladderCA
2
9
70
In the future we won’t rely on pathology at surgery +/- luck to select patients for adjuvant treatment across cancers. Instead, the identification of residual disease by ctDNA/other biomarkers will be used. These data are a step towards that goal IMO. https://t.co/dPqlvr2rnV
4
69
190
We need more and more people like Phil and Penny Knight ! @NikeUnleash @Nike
Phil and Penny Knight announced today a record-breaking $2 billion gift to the Oregon Health & Science University’s Knight Cancer Institute to transform the future of cancer care and set a new standard globally. Thank you to Phil and Penny Knight for their incredible generosity.
1
2
34
The +ve periopertive EVP trial for OS in cis ineligible MIBC may open a new area. Especially if its like EVP in M1 disease. 3 more trials in this area are awaited which test 1) EVP vs cisplatin (NIAGARA population), 2) EV/PD1/CTLA4 vs surgery 3) treatment based on ctDNA status.
3
60
138
Perioperative EVP shows ⬆️ EFS,OS & pCR vs cystectomy alone in high risk cisplatin ineligible MIBC (KN901). Highly active systemic vs surgery will rescue many patients with aggressive micrometastatic disease. CRs for EVP=30% in M1 but should be ⬆️ in MIBC https://t.co/MEsZvzktTe
5
78
206
Register now: 2025 FDA-AACr-SITC workshop: approach to novel oncology endpoint development. Sep 11, 2025 inperson or virtual. https://t.co/pV7EPmI1JW
1
12
50
📢🗣️ New trial analysis from #FASTRACKII: in kidney cancer, SABR ⬆️ efficacy and ⬇️ cost than radiofrequency or cryoablation #kcsm #radonc 🔹 QALYs: SABR 4.00 vs RFA/CA 3.07 🔹 Cost: SABR A$31,053 vs RFA A$35,001 vs CA A$36,356 🔹 Net savings ~$4K/patient https://t.co/2NoT7g94EP
5
74
146
Please check out our editorial just out in @NatRevUrol on a pragmatic approach to biomarkers for RCC! Many challenges, but with now some emerging promising biomarkers! @arihakimi @EdReznik @motzermd
@MSKCancerCenter @MSK_DeptOfMed
https://t.co/CaRdSBJP51
3
33
88
Longer follow up for Enfortumab Vedotin & Pembro in urothelial cancer @Annals_Oncology shows mOS at nearly 3 yrs (34 mnths) with 50% of responses (68%) continuing at 2 years! Experience in tox management is important. Duration of therapy uncertain in CR https://t.co/P79G9mCRj7
1
57
163
Chromophobe renal cell carcinoma is difficult to treat - Research in @JCO_ASCO provides better understanding of this rare kidney cancer, potential treatment pathways & immunotherapy strategies. @DanaFarber_GU @eddy_saad @Chrislabaki1 @BIDMChealth ➡️
ascopubs.org
PURPOSEWhile immune checkpoint inhibition (ICI) has transformed the management of many advanced renal cell carcinomas (RCCs), the determinants of effective antitumor immunity for chromophobe RCC...
0
10
34
The 4th live Uromigos meeting is happening on 7th & 8th Nov ‘25 in Nashville. It’s going to have an international flavour with America’s 🇺🇸 🇨🇦 vs Eurasia 🇯🇵 🇨🇳 🇮🇳 🇦🇺 🇪🇺 Uromigos Cup competition (details to follow). Sessions ranging from ADCs in MIBC to the changing shape of
0
16
45
Gem/cis/durvalumab is approved in the EU for muscle invasive bladder cancer (NIAGARA study). It’s the only immune therapy study in the adjuvant or neoadjuvant setting with significant OS. ⬆️ pCR and EFS support this appr @OncoAlert @Annals_Oncology
https://t.co/EfftVBphaF
0
63
164
1/ Recently, our lab has worked with outstanding groups (#TeamScience) to address some key questions in kidney cancer immunobiology: Can we use machine-learning approaches to classify RCC and predict response? @Cancer_Cell What drives exceptional response with immunotherapies?
4
16
106
17/ Next, we use @IMDConline @DrDanielHeng to interrogate the clinical outcomes (TTF, OS, ORR) of patients with metastatic ChRCC vs. ccRCC, across various 1L regimens: -Significantly poorer outcomes with 1L ICI-based regimens in ChRCC vs. ccRCC -Similar outcomes with 1L VEGF-TT
1
2
4
Bravo @Chrislabaki1 @eddy_saad both now @BIDMC_IM for a landmark paper about Chromophobe Kidney Cancer. A tumor that remain a mystery in biology, but less so after this work. Wonderful mentorship from @BraunMDPhD @VanAllenLab @ShuklaSachet @LisaHenske ! CC: @YaleCancer
1/ Thrilled to share our work on Chromophobe RCC (ChRCC) and Renal Oncocytic Neoplasms (RONs) out @JCO_ASCO !!! Incredibly thankful to my mentors @BraunMDPhD @DrChoueiri @VanAllenLab and all co-authors @DanaFarber @BIDMC_IM @Yale @BrighamWomens Link:
0
14
50
News From Industry Source: AstraZeneca The European Commission has approved AstraZeneca’s Imfinzi (durvalumab) as the first and only perioperative immunotherapy for resectable muscle-invasive #BladderCancer (MIBC), based on results from the Phase III NIAGARA trial. In
1
17
38
Go @DrDanielHeng!
0
2
13